




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 305/14, A61K 31/335	A1	(11) International Publication Number: WO 99/52887 (43) International Publication Date: 21 October 1999 (21.10.99)
(21) International Application Number: PCT/US99/07880 (22) International Filing Date: 9 April 1999 (09.04.99) (30) Priority Data: 09/058,036 10 April 1998 (10.04.98) US (71) Applicant: HAUSER, INC. [US/US]; 5555-Airport Boulevard, Boulder, CO 80301 (US). (72) Inventors: MURRAY, Christopher, K.; 3903 Pebble Beach Drive, Longmont, CO 80503 (US). ZHENG, Qun, Y.; 6 Fox Hill Drive, Wayne, NJ 07470 (US). SHAKYA, Sagar, R.; Apartment 701, 9 Bonheur Court, Brantford, Ontario (CA). (74) Agents: YOUNG, James, R. et al.; Chrisman, Bynum & Johnson, P.C., 1900 Fifteenth Street, Boulder, CO 80302 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>

(54) Title: 7-HEXANOYLTAXOL AND METHODS FOR PREPARING THE SAME**(57) Abstract**

An antitumor compound of formula (5). Also provided by the present invention is a method of preparing a compound of formula (5) whereby diesterification of the alcohol groups located at the 2' and 7 positions of paclitaxel is followed by the hydrolysis of the 2' hexanoate group resulting in 7-hexanoyltaxol.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

7-Hexanoyltaxol and Methods for Preparing the Same

Description

Cross-Reference to Related Patent Applications

This patent application references Disclosure Document entitled "Preparation Of 7-Hexanoyltaxol: A Novel Paclitaxel Derivative," No.: 396746, filed April 10, 1996.


Technical Field

The present invention relates to a paclitaxel derivative which exhibits an antitumor activity greater than that of paclitaxel. Specifically, the present invention relates to a novel antitumor agent that is formed through the initial diesterification of the alcohol groups located at the 2' and 7 positions of paclitaxel followed by the selective hydrolysis of the ester located at the 2' position thereby resulting in a 7-acyltaxol product.

Background Art

Between the years 1958 and 1980, extracts of over 35,000 plant species were tested for anticancer activity as part of an NCI-sponsored program. Chemists Monroe E. Wall and M. C. Wani first isolated a crude extract concentrate from yew tree (*Taxus brevifolia*) bark and wood samples in 1963. Initial screening showed the extract to be a potential anticancer agent, being very active against an unusually wide range of rodent cancers. Isolation of the active agent in the crude extract took several years due to the very low concentrations of the agent present in the plants. The active agent was identified, the structure determined and the compound, in 1971, was named taxol, which is now generically referred to as paclitaxel (1).

(1)




The naturally occurring diterpenoid, paclitaxel (1), is one of the most exciting discoveries in the field of cancer chemotherapy. In 1979, Susan B. Horwitz and co-workers established that, while paclitaxel was an antimiotic inhibitor, the mechanism was unique in that it stabilizes microtubules and inhibits depolymerization back to tubulin; this was quite the opposite effect of other antimiotic agents which all bind to soluble tubulin and inhibit the polymerization of tubulin to form

microtubules. See, *Nature*, **227**:655-667 (1979). Thus, taxol increases the time required for cell division which in turn inhibits tumor activity.

Since the discovery of paclitaxel, over one hundred compounds having the taxane skeleton have been isolated from various *Taxus* species, listed below are but a few of the representative structures of the more notable taxol analogues.

(2)



10	(b) Paclitaxel (taxol A)	R ₁ = H	R ₂ = Ac	R ₃ = C ₆ H ₅
	(c) Cephalomannine (taxol B)	R ₁ = H	R ₂ = Ac	R ₃ = CH ₃ CH=C(CH ₃)
	(d) Taxol C	R ₁ = H	R ₂ = Ac	R ₃ = n-C ₅ H ₁₁
	(e) 10-deacetyltaxol A	R ₁ = R ₂ = H		R ₃ = C ₆ H ₅
	(f) 10-deacetyltaxol B	R ₁ = R ₂ = H		R ₃ = CH ₃ CH=C(CH ₃)
15	(g) 10-deacetyltaxol C	R ₁ = R ₂ = H		R ₃ = n-C ₅ H ₁₁

Despite paclitaxel's excellent activity in model tumor systems, research progressed at a rather a slow pace and its development was fraught with many obstacles including scarcity of the drug (owing to low abundance of Yew tissue), extremely low aqueous solubility, and toxicities. Problems in drug supply have largely been alleviated, not only as a result of more efficient collection and extraction of plant material, but also because of the progress made in the complete and semi-synthesis of the compound paclitaxel. Three total synthesis have been carried out to date. The Holden group and Nicolaou group published their approaches in 1994, and more recently, Danishefsky and co-workers reported their route to paclitaxel. See, *J. Am. Chem. Soc.*, **116**:1597- 1599 (1994); *Nature*, **367**:630 (1994), *J. Chem. Soc. Chem. Commun.*, 295 (1994), and *J. Am. Chem. Soc.*, **116**:1591 (1994); and *J. Am. Chem. Soc.*, **118**:2843 (1996), respectively, and which are hereby incorporated by reference. The extremely low aqueous solubility and toxicity obstacles, however, remain more difficult to overcome.


Paclitaxel is a complex diterpenoid which comprises a bulky, fused ring system and an extended side chain at the C-13 position that is required for activity. This complex structure further

contains 11 chiral centres with 2048 possible diastereoisomeric forms. Relatively hydrophilic domains exist in the molecule around the vicinity of the C-7 through C-10 and C-1' through C-2' positions. However, hydrophobic domains of the taxane backbone and side chain contribute to the overall poor aqueous solubility of the compound. In order to administer human doses in a reasonable volume, paclitaxel is currently formulated for clinical use in a mixture of anhydrous ethanol and polyethoxylated castor oil (Cremophor EL®), a clear, oily, viscous, yellow surfactant. In addition to the potential problems of physical instability, the most significant problem with the current clinical paclitaxel formulation is that the Cremophor EL® vehicle possesses pharmacological activity. While a variety of drugs are administered in Cremophor EL®, the dose of Cremophor EL® that accompanies a dose of paclitaxel is the highest for any marketed drug. Cremophor EL® has been observed to cause serious or fatal hypersensitivity episodes, and vehicle toxicity may be largely responsible for fatal or life-threatening anaphylactic reactions observed upon rapid infusion of paclitaxel into animals or humans.

In light of the serious risks associated with the current intravenous formulations of paclitaxel, efforts to develop safe, convenient, and efficacious paclitaxel formulations are ongoing. However, the majority of approaches underway to solve the problems associated with paclitaxel are the synthesis and evaluation of a second generation of paclitaxel analogues.

10-deacetylbaccatin III (2) and baccatin III (3)

(3)




(2) 10-deacetyl baccatin III, R = H

(3) baccatin III, R = Ac

are diterpenes that are more readily available than paclitaxel and are known synthetic precursors of paclitaxel and its analogues. Their structural complexity is less than that of paclitaxel's and therefore, 10-deacetylbaccatin III (2) and baccatin III (3) are also valuable starting materials for structural modifications at the diterpene part of the paclitaxel molecule.

10-deacetylbaccatin III was used as the starting material for the semisynthetic compound docetaxel (4) commonly referred to as Taxotère®, developed by French researchers from the Institut de Chimie de Substances Naturelles and Rhône-Poulenc Rorer in 1981.

(4)




The lateral side chain located at C-13 position, which is responsible for its cytotoxic effect, is added chemically. Docetaxel differs structurally from paclitaxel at the C-10 position on the baccatin ring and at the C-3' position on the lateral side chain. See, "Biologically Active Taxol Analogues with Deleted A-Ring Side Chain Substituents and Variable C-2' Configuration," *J. Med. Chem.*, **34**:1176-1184 (1991); "Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity," *J. Med. Chem.*, **34**:992-998 (1991). Docetaxel is twice as potent an inhibitor of microtubule depolymerization as paclitaxel. The *in vitro* cytotoxicity of docetaxel in murine and human tumor cell lines and its *in vivo* preclinical activity in murine and human xenografts have been impressive. Docetaxel has displayed higher cytotoxic activity than other antineoplastic agents such as paclitaxel, cisplatin, cyclophosphamide, and doxorubicin against the same tumor models. While docetaxel is a promising antitumor agent with a broad spectrum it, like paclitaxel, suffers low aqueous solubility. The fact remains however, that a potent analogue of paclitaxel having promising activity was developed by making a simple side chain modifications at the 3' amide. Encouraged by this exciting result other researchers began modifications to each position of the diterpene core hoping to develop a structural analogue of paclitaxel which overcomes the problems associated with paclitaxel; however, to date, none have been developed.

There is still a need, therefore, for developing structural analogues of paclitaxel which have less formulation problems and equivalent or greater potency than that of paclitaxel.

Disclosure of Invention

Accordingly, it is an object of this invention to provide a structural analogue of paclitaxel which demonstrates antitumor activity and a method for the preparation of the same. More specifically the present invention provides a paclitaxel derivative of formula (5)

(5)



having antitumor activity.

5 Another object of the present invention is to provide a method for the preparation of 7-hexanoyltaxol.

Additional objects, advantages and novel features of this invention shall be set forth in part in the description and examples that follow, and in part will become apparent to those skilled in the art upon examination of the following specification or may be learned by the practice of the invention.

10 The objects and advantages of the invention may be realized and attained by means of the instrumentalities, combinations, compositions, and methods particularly pointed out in the appended claims.

To achieve the foregoing and other objects and in accordance with the purposes of the present invention, as embodied and broadly described therein the method, and compositions produced thereby, of this invention comprises converting the alcohols located at the 2' and 7 positions of paclitaxel to esters, resulting in an intermediate composition. Selective hydrolysis of the 2'-ester leads to the desired product.

Brief Description of the Drawings

20 The accompanying drawings, which are incorporated in and form a part of the specification, illustrate the preferred embodiments of the present invention, and together with the description serve to explain the principles of the invention.

In all of the drawings which follow, the horizontal axis depicts various dilutions of the test compound, ranging from 10^{-4} to 10^{-14} molar, that were exposed to a specified cancer. The vertical axis (percentage growth) depicts the growth of the specified cancer cell line when exposed to a specific concentration of the tested compound as compared to the growth of the same cancer cell line not exposed to any compound.

25 Figure 1 depicts a schematic illustrating the various synthetic routes used in the preparation of the compositions of the present invention.

Figure 1a depicts a schematic illustrating the preferred method of preparing the preferred composition of the present invention

Figure 2a depicts the dose response curves generated by exposing various leukemia cell lines to various concentrations of the composition of the present invention.

5 Figure 2b depicts the dose response curves generated by exposing various leukemia cell lines to various concentrations of paclitaxel.

Figure 3a depicts the dose response curves generated by exposing various non-small cell lung cancer cell lines to various concentrations of the composition of the present invention.

10 Figure 3b depicts the dose response curves generated by exposing various non-small cell lung cancer cell lines to various concentrations of paclitaxel.

Figure 4a depicts the dose response curves generated by exposing various colon cancer cell lines to various concentrations of the composition of the present invention.

Figure 4b depicts the dose response curves generated by exposing various colon cancer cell lines to various concentrations of paclitaxel.

15 Figure 5a depicts the dose response curves generated by exposing various CNS cancer cell lines to various concentrations of the composition of the present invention.

Figure 5b depicts the dose response curves generated by exposing various CNS cancer cell lines to various concentrations of paclitaxel.

20 Figure 6a depicts the dose response curves generated by exposing various melanoma cell lines to various concentrations of the composition of the present invention.

Figure 6b depicts the dose response curves generated by exposing various melanoma cell lines to various concentrations of paclitaxel.

Figure 7a depicts the dose response curves generated by exposing various ovarian cancer cell lines to various concentrations of the composition of the present invention.

25 Figure 7b depicts the dose response curves generated by exposing various ovarian cancer cell lines to various concentrations of paclitaxel.

Figure 8a depicts the dose response curves generated by exposing various renal cancer cell lines to various concentrations of the composition of the present invention.

30 Figure 8b depicts the dose response curves generated by exposing various renal cancer cell lines to various concentrations of paclitaxel.

Figure 9a depicts the dose response curves generated by exposing various prostate cancer cell lines to various concentrations of the composition of the present invention.

Figure 9b depicts the dose response curves generated by exposing various prostate cancer cell lines to various concentrations of paclitaxel.


Figure 10a depicts the dose response curves generated by exposing various breast cancer cell lines to various concentrations of the composition of the present invention.

Figure 10b depicts the dose response curves generated by exposing various breast cancer cell lines to various concentrations of paclitaxel.

5 Best Mode for Carrying out the Invention

The present invention provides a novel taxol derivative of formula (7)

(7)



10 wherein R may be a monovalent organic compound, a monovalent aliphatic compound such as a hydrocarbon or a hetero-acyclic group, or a monovalent cyclic group such as an alicyclic or aromatic group wherein the monovalent alicyclic group comprises monovalent carbocyclic and heterocyclic groups and the monovalent aromatic group comprises monovalent carboaromatic groups and monovalent hetero-aromatic groups. More specifically R may be a branched or unbranch alkyl, 15 alkenyl, alkynyl group or an aryl group, the synthesis of which can be accomplished by a wide variety of methods.

As shown in Figure 1, the alcohols located at the 2' and 7 positions of the paclitaxel compound (1) may be converted to esters prepared by adding a reagent, such as a carboxylic acid, an acid halide or an acid anhydride, having the desired R group, to a solution of paclitaxel. The 20 necessary reaction conditions for preparing esters from alcohols are well known and understood in the art. The resulting intermediate (6) is subsequently purified and the ester located at the 2' position is either hydrolyzed or reduced resulting in product (7).

In the preferred embodiment, shown in Figure 1a, a compound of formula (5), is produced by mixing an acid anhydride, such as hexanoic acid, to a mixture of paclitaxel (1). The diesterification 25 of the alcohols located at the 2' and 7 positions of paclitaxel result in an intermediate *bis* 2', 7-hexanoyltaxol compound. The selective removal of the 2'-hexanoate group by hydrolysis results in the desired 7-hexanoyltaxol compound (5).

To determine the cytotoxicity of 7-hexanoyltaxol as compared to taxol, screening assays were

performed; these activities are summarized in Table I (set out below). The screening assay is performed on 96-well microtitre plates. Relatively high initial inoculation densities are used, in order to permit measurement of "time-zero" values and to enhance the screen's ability to detect and provide some differentiation between antiproliferative and cytotoxic response parameters. The specific inoculation densities (which range from 5,000 to 40,000 cells/well) used for each cell line are those which, for the respective line, were determined to give an optical density signal for both the "time-zero" value (at 24 hours) and the "no-drug" control (at 72 hours) above the noise level and within the linear range of the end-point assay (which measures cellular protein). The inoculated microtitre plates are pre-incubated for 24 hours at 37°C prior to drug additions. The five drug dilutions tested routinely range from 10^{-4} to 10^{-8} molar. Higher or lower concentration ranges may be selected on a nonroutine basis if appropriate solubility and/or prior biological information or other screening data so dictate. Duplicate wells are prepared for all concentrations; "time-zero" and "no drug" controls are also provided for each test. The minimum amount of compound required for a 1-time evaluation in the routine screen can be calculated from the knowledge that each test requires a total of approximately 40 ml (0.04 liter) of cell culture medium containing the highest desired drug concentration. Thus, the amount (grams) of sample required (assuming an upper test concentration limit of 10^{-4} M) is: molecular weight of compound $\times 10^{-4} \times 0.04$. After a 48 hour incubation (37°C) with the test compound, the cells are fixed *in situ* to the bottoms of the microtitre wells by addition of 50 μ l of either 50% trichloroacetic acid (for adherent cell lines) or 80% trichloroacetic acid (for settled cell suspension lines), followed by incubation for 60 minutes at 4°C. The cellular protein in each well is assayed using a sulfarhodamine B (SRB) stain procedure. Briefly, after discarding the supernatants, the microtitre plates are washed 5 times with deionized water and air-dried. One hundred microliters of SRB solution (0.4% w/v in 1% acetic acid) is added to each microtitre well and incubated for 10 minutes at room temperature. Unbound SRB is removed by washing 5 times with 1% acetic acid. The plates are air-dried, the bound stain is solubilized with Tris buffer, and the optical densities read at 515nm. SRB is a bright pink anionic dye which, in dilute acetic acid, binds electrostatically to the basic amino acids of TCA-fixed cells. Cryopreserved master stocks of all the lines are maintained, and cultures used for screening are replaced from the master stock after no more than twenty passages in the screening laboratory. The cell line panel consists of 60 lines, organized into nine, disease-related subpanels including leukemia, non-small-cell lung cancer, colon, CNS, melanoma, ovarian, renal, prostate and breast cancers.

The response parameters GI_{50} and LC_{50} are interpolated values representing the concentrations at which the percentage growth (PG) is +50 and -50 respectively:

GI_{50} is the concentration for which the $PG=+50$. At this value the increase from time t_{zero} in

the number or mass of cells in the test well is only 50% as much as the corresponding increase in the control well during this period of the experiment. A drug effect of this intensity is interpreted as primary growth inhibition.

TGI is the concentration for which $PG=0$. At this value the number or mass of cells in the well at the end of the experiment equals the number or mass of cells in the well at time t_{zero} . A drug effect of this intensity is regarded as cytostasis.

LC_{50} is the concentration for which the $PG=-50$. At this value, the number or mass of cells in the test well at the end of the experiment is half that at time t_{zero} . This is interpreted as cytotoxicity.

TABLE I

Panel/Cell line	$\log_{10} GI_{50}$		$\log_{10} TGI$		$\log_{10} LC_{50}$	
	7-Hexanoyl-taxol	Paclitaxel	7-Hexanoyl-taxol	Paclitaxel	7-Hexanoyl-taxol	Paclitaxel
Leukemia						
CCRF-CEM	< -8.00	-11.61	< -8.00	> -4.00	> -4.00	> -4.00
HL-60(TB)	< -8.00	-11.57	< -8.00	> -4.53	> -4.00	> -4.00
K-562	< -8.00	-10.83	-7.05	> -4.00	> -4.00	> -4.00
MOLT-4	< -8.00	-11.07	-4.69	> -4.00	> -4.00	> -4.00
RPMI-8226	< -8.00	< -13.00	> 4.00	> -4.00	> -4.00	> -4.00
SR	< -8.00	-8.34	---	> -4.00	> -4.00	> -4.00
Non-Small Cell Lung Cancer						
EKVX	-6.40	---	-4.29	---	> -4.00	> 4.00
HOP-62	-7.85	-9.67	-6.52	-4.80	-4.05	-4.05
NCI-H226	< -8.00	---	-4.76	---	> -4.00	> 4.00
NCI-H23	< -8.00	---	-4.86	---	-4.34	-4.34
NCI-H322M	-7.70	-10.12	-4.51	-4.46	> -4.00	> -4.00
NCI-H460	< -8.00	-12.16	-4.75	-4.92	> -4.00	> -4.00
NCI-H522	< -8.00	< -13.00	-5.91	-11.20	> -4.00	> -4.00
Colon Cancer						
COLO 205	< -8.00	-11.07	-7.38	---	-4.58	> -4.58
HCC-2998	< -8.00	-12.34	-7.35	-4.77	-5.08	-5.08
HCT-116	< -8.00	< -13.00	-4.94	-4.82	> -4.00	> -4.00
HT29	< -8.00	< -13.00	-4.95	---	-4.48	-4.48
KM12	< -8.00	-11.43	-4.90	-4.36	> -4.00	> -4.00
SW-620	< -8.00	-11.60	> -4.00	> -4.00	> -4.00	> -4.00

	CNS Cancer					
	SF-268	< -8.00	---	-4.95	---	> -4.00
	SF-295	< -8.00	---	-6.41	---	> -4.00
5	SF-539	< -8.00	-11.09	-7.32	---	-5.82
	SNB-19	-7.99	-8.98	-4.53	> -4.00	> -4.00
	SNB-75	< -8.00	---	-7.41	---	> -4.00
	U251	< -8.00	-11.29	-4.98	-4.32	-4.49
	Melanoma					
10	LOX-IMVI	---	-11.80	-4.68	-4.65	-4.24
	MALME-3M	< -8.00	---	-4.65	-4.46	-4.09
	M14	< -8.00	-11.73	-7.94	-4.62	-5.80
	SK-MEL-2	-7.03	-9.53	-4.56	---	> -4.00
	SK-MEL-28	< -8.00	---	-4.33	---	> -4.00
15	SK-MEL-5	< -8.00	---	-4.56	---	> -4.00
	UACC-257	---	-10.30	-4.00	-4.52	> -4.00
	UACC-62	< -8.00	-10.46	-4.78	-4.71	> -4.00
	Ovarian					
20	IGR-OV1	< -8.00	-8.61	-4.52	-4.19	> -4.00
	OVCAR-3	< -8.00	-10.40	-7.65	-4.55	-4.68
	OVCAR-4	-5.80	-5.80	-4.21	-4.19	> -4.00
	OVCAR-5	< -8.00	-9.38	-5.47	-4.92	-4.47
	OVCAR-6	< -8.00	-10.75	-4.88	---	-4.07
	SK-OV-3	< -8.00	---	-4.84	---	-4.04
25	Renal Cancer					
	786-0	< -8.00	-8.01	-4.88	> -4.00	-4.44
	A498	< -8.00	-7.14	-7.29	---	> -4.00
	ACHN	-7.02	---	> -4.00	---	> -4.00
	CAKI-1	-6.58	---	-4.52	---	> -4.00
30	RXF-393	< -8.00	-8.32	< 8.00	-4.90	-4.04
	SN12C	< -8.00	-9.53	> -4.00	-4.04	> -4.00
	TK-10	-7.49	-7.89	-4.45	> -4.00	> -4.00
	UO-31	-7.19	-6.09	> -4.00	-4.29	> -4.00
35	Prostate Cancer					
	PC-3	< -8.00	-10.85	-5.48	> -4.00	> -4.00
	DU-145	< -8.00	-9.38	-7.00	> -4.00	-4.43

5	Breast Cancer					
	MCF7	< -8.00	-11.69	-4.73	-4.05	> -4.00
	MCF7/ADR-RES	-5.95	-8.48	-4.80	> -4.00	> -4.00
	MDA-MB-231/ATCC	-7.55	-8.54	-6.13	-4.84	-4.63
	MDA-MB-435	< -8.00	< -13.00	< -8.00	---	< -8.00
	MDA-N	< -8.00	< -13.00	< -8.00	---	< -8.00
	SK-BR-3	< -8.00	---	-6.04	---	> -4.00
	MDA-MB-468	< -8.00	---	-6.26	---	> -4.00
10	MAXF 401	< -8.00	---	< -8.00	---	---
	MG_MID	-7.79	-10.15	-5.59	-4.54	-4.32
	Delta	0.21	---	2.41	---	3.68
	Range	2.14	8.00	4.00	7.20	4.00
						0.45

The 7-hexanoyltaxol compound of the present invention in most instances is as potent and in some instances more potent than paclitaxel. The data represented in Table I is graphically represented in Figures 2a and 2b through Figures 10a and 10b. Dose response curves, depicted in the above mentioned Figures, are obtained by exposing various cancer cell lines to compounds that have a known concentration ($[\log_{10}M]$), as discussed in detail above, and then plotting the percentage growth of each cell line at each concentration. Percentage growth is determined by dividing the number or mass of cells in the test well by the number or mass of the cell in a control well. The following is an example of how the information in Table I and in the Figures is interpreted.

Referring to the leukemia cell line CCRF-CEM, in Figures 2a and 2b the first comparison that is made between the compound of the present invention, 7-hexanoyltaxol, and paclitaxel are the concentrations of the two drugs which are necessary to inhibit growth, graphically represented as in Figures 2a and 2b as the concentration necessary to achieve the value of +50. As discussed previously, the five drug dilutions routinely tested range from 10^{-4} to 10^{-8} molar. Therefore, concentrations less than or greater than 10^{-8} and 10^{-4} molar, respectfully, that are required to achieve a desired result are not determined. Referring now to Figure 2a, a concentration of approximately 10^{-7} molar is necessary to achieve primary growth inhibition for the compound of the present invention. The lower concentrations for paclitaxel, however, have been determined for this drug and the concentration at which primary growth inhibition occurs using paclitaxel is -11.61 molar, see Figure 2b. The concentration at which 7-hexanoyltaxol is considered cytostasis, i.e. percentage growth is equal to 0, is -6.1 molar, while an equivalent intensity using paclitaxel is achieved at a concentration greater than -4.00 molar. Cytotoxicity, i.e., the concentration for which the percentage growth is equal to -50, occurs for both drugs at some concentration greater than -4.00 molar.

The potency of the 7-hexanoyltaxol compound (5) of the present invention as compared to paclitaxel varies from cell line to cell line. However, on the whole, the potency of 7-hexanoyltaxol was found to be equivalent to and in many instances greater than that of paclitaxel's. The mean values for both 7-hexanoyltaxol and paclitaxel are listed at the end of the Table I. When interpreting these numbers, however, it is important to take into consideration that values above 10^{-8} and below 10^{-4} were not collected, this factor is reflected in the range.

The compound of the present invention was further tested on multidrug resistant cell lines. The resistance of cancer cells to multiple chemotherapeutic drugs which are structurally unrelated has been termed "multidrug resistance." In the past several years, several mechanisms of multidrug resistance have been described, including the expression of a cell surface multidrug efflux pump (P-glycoprotein or the multidrug transporter), altered glutathione metabolism, reduced activity of topoisomerase II, and various less clearly defined changes in cellular proteins. Because of evidence that expression of P-glycoprotein is associated with drug-resistance in cancer, P-glycoprotein has been studied extensively from the point of view of its biochemistry and mechanism of action in order to develop inhibitors which can be used clinically to reverse drug resistance of cancers in patients. The clinical significance of the other mechanisms of multidrug resistance are less well-established, but many model systems indicate that they may contribute to clinical resistance.

Surprisingly, compound of the present invention is effective in treating cancer cell lines that exhibit multidrug resistance. To determine the effect of 7-hexanoyltaxol (5) as compared to paclitaxel on multidrug resistant cell lines, screening assays were performed; the results are summarized in Table 2 below.

Table 2

Compound	26 Cell lines ($\mu\text{g/ml}$)		MDR	ρ	Tubulin	G2/M arrest
	Mean IC50	Min IC50			ED50	MED($\mu\text{g/ml}$)
7-hexanolytaxol	0.008	0.001	1	0.67	4.3	0.10
Taxol	0.020	0.001	158	1.00	2.1	0.025

KEY: Mean IC50 : 26 cell line Mean Growth inhibition IC50 value ($\mu\text{g/ml}$) .48 hour drug treatment, sulforhodamine stain.

Min IC50 : Lowest observed IC50 value in 26 cell line screen.

MDR : The ratio of two IC50 values, where the numerator is an MDR⁺ cell line. Higher numbers = less effective vs. MDR (multidrug resistant) cells.

- rho : Mean Graph correlation coefficient, where 1 = identical pattern as Taxol;
0.85 - 0.95 = close match; 0.75 - 0.85 = good match; ≤ 0.75 = poor match.
- Tubulin ED50 : Concentration of taxane that causes 50% of purified calf-brain tubulin to
to polymerize compared to the amximum polymerization produced by the
the GRP control (1 mM).
- G2/M arrest : Minimum concentration of taxane that results in 60% of CCRF-CEM
cells to arrest in G2-M.

The 7-hexanoyltaxol compound (5) of the present invention is vastly more effective than
paclitaxel against multidrug resistant cell lines.

The following non-limited example provides a specific high yield process for preparing 7-hexanoyltaxol. All scientific and technical terms have the meanings as understood by one with ordinary skill in the art. The synthetic descriptions and specific examples that follow are only intended for the purposes of illustration, and are not to be construed as limiting in any manner to make compounds of the present invention by other methods. The methods may be adapted to variation in order to produce compounds embraced by this invention but not specifically disclosed. Further, variations of the methods to produce the same compounds in somewhat different fashion will be evident to one skilled in the art.

All temperatures are understood to be in Centigrade ($^{\circ}\text{C}$) when not specified. The nuclear magnetic resonance (NMR) spectral characteristics refer to chemical shifts δ expressed in parts per million (ppm) versus tetramethylsilane (TMS) as reference standard. ^1H and ^{13}C NMR spectra were recorded on a Varian Gemini-400 instrument or JEOL Eclipse-400. The relative area reported for the various shifts in the proton NMR spectral data corresponds to the number of hydrogen atoms of a particular functional type in the molecule. The nature of the shifts as to multiplicity is reported as broad singlet (bs), broad doublet (bd), broad triplet (bt), broad quartet (bq), singlet (s), multiple (m), doublet (d), quartet (q), triplet (t), doublet of doublet (dd), doublet of triplet (dt), and doublet of quartet (dq). The solvents employed for taking NMR spectra are DMSO- d_6 (perdeuterodimethylsulfoxide), D_2O deuterated water), CDCl_3 (deuterochloroform) and other conventional deuterated solvents. The chemical shifts are expressed in ppm relative to the reference of CDCl_3 or DMSO. Deuterated solvents were purchased from Aldrich Chemical Co. The infrared (IR) spectral description was measured on a KVB Analect Diamond-20 FT-IR Spectrometer featuring a Laser Precision XAD-Plus Microscope. Electrospray mass spectra were obtained from a VG Platform HPLC-MASS Spectrometer. TLC plates of silica gel 60F254 were purchased from E.M. Merck and kept in a closed container over Drierite® prior to use. Melting points were measured on a

MEL-TEMP II apparatus equipped with a digital Barnant 100 Thermocouple Thermometer and are uncorrected. HPLC was performed on a Hitachi chromatographic spectrometer (L-6200A Intelligent Pump, D-6000 Interface, L-4000 UV Detector and AS-4000 Intelligent Auto Sampler). Combination of CH₃CN and H₂O in different concentrations are used as HPLC solvent system. All solvents were distilled before use. Commercially available chemicals were used without any further purification. Various methods of purifying the products of the present invention are known and understood by those skilled in the art and the purification methods presented in the Examples is solely listed by way of example and is not intended to limit the invention.

EXAMPLE I

(I) Preparation of *bis* 2',7-Hexanoyltaxol:

Hexanoic anhydride 4.47 mL, 19.325 mmol) was added to a solution of paclitaxel (3.30 g, 3.865 mmol) and DMAP (0.047 g, 0.386 mmol) in 30 mL of CH₂Cl₂ at 0°C. The reaction mixture was stirred over a range of approximately 0-25°C for 18 hours. The reaction mixture was quenched with 5% NaHCO₃, and extracted with 3 X 25 mL of CH₂Cl₂. The combined organic layer was washed with water, and brine and dried with anhydrous MgSO₄. The crude product was purified in two batches by silica gel column chromatography (4 X 25 cm silica columns, 2.5 MeOH/CH₂Cl₂) to provide 4.24 g (104%) of pure *bis*-2',7-hexanoyltaxol and 0.6 g (15%) of product contaminated with a slower spot. This excess mass is due to the residual anhydride and acid impurities. Thus, the pure fraction was dissolved in 30 mL of CH₂Cl₂ and washed with 5% NaHCO₃ solution. The aqueous layer was extracted with 3 X 15 mL of CH₂Cl₂. The organic phase was dried with anhydrous MgSO₄ and concentrated in vacuo to provide 3.146 g (78%) of *bis*-2',7-hexanoyltaxol as a white solid: melting point 124-128° C; ¹H NMR (400 MHz, CDCl₃) δ 0.84 - 0.90 (m, 12H), 1.14 (s, 3H), 1.18 (s, 3H), 1.23 - 1.33 (m, 16H), 1.53 - 1.68 (m, 8H), 1.56 (s, 3H), 1.78 (s, 3H), 1.79 (m, 1H), 1.98 (s, 3H), 2.12 - 2.24 (m, 1H), 2.30 - 2.44 (m, 10H), 2.42 (s, 3H), 2.59 (m, 1H), 3.93 (d, J=7.0 Hz, 1H), 4.16 (d, J=8.4 Hz, 1H), 4.31 (d, J=8.4 Hz, 1H), 4.94 (dd, J=1.0, 8.0 Hz, 1H), 5.52 (d, 3.3Hz, 1H), 5.57 (dd, J=7.0, 10.2 Hz, 1H), 5.66 (d, J=6.6 Hz, 1H), 5.92 (dd, J=3.7, 9.0 Hz, 1H), 6.20 (dd, J=8.8, 8.8 Hz, 1H), 6.26 (s, 1H), 6.88 (d, J=9.2 Hz, 1H), 7.32 - 7.42 (m, 7H), 7.48 - 7.52 (m, 3H), 7.59 (m, 1H), 7.73 (m, 2H), 8.10 (m, 2H) - some residual hexane solvent present; LRMS (electrospray) M/Z observed for C₅₉H₇₁NO₁₆Na (M + Na): 1072.9.

(II) Hydrolysis of the 2'-hexanoate group:

NaHCO₃ (12.54 g, 149.8 mmol) was added to a mixture of *bis*-2',7-hexanoyltaxol (3.15 g, 3.0 mmol), H₂O₂ (30%, 10.08 mL), and THF (122 mL). The reaction mixture was stirred for 8 hours at room temperature and stored in a refrigerator overnight. Then the mixture was stirred for an additional 2 hours. Since the starting material has not yet been completely hydrolyzed about 100 mL of water was added and the mixture was stirred for an additional 6 hours. The reaction mixture was quenched with


5% citric acid carefully. The aqueous phase was extracted with 3 X 100 mL of CH_2Cl_2 . The combined organic phase was washed with 20% $\text{Na}_2\text{S}_2\text{O}_3$ and brine, dried with anhydrous MgSO_4 , and concentrated in vacuo to give a crude product. Repeated flash silica gel column chromatography (2% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ for first column, 10-20% $\text{EtOAc}/\text{CH}_2\text{Cl}_2$ for second column) gave calculated 1 g (approximately 35%) of impure 7-hexanoyltaxol and 1.5 g (approximately 53%) of pure 7-hexanoyltaxol as a white solid: Melting Point 149 - 154°C; ^1H NMR (400 MHz, CDCl_3) δ .86 (t, 7.0 Hz, 3H), 1.16 (m, 4H), 1.13 (m, 5H), 1.56 (m, 2H), 1.80 (s, 3H), 1.82 (m, 1H), 1.82 (s, 3H), 2.14 (s, 3H), 2.18 - 2.40 (m, 5H), 2.36 (s, 3H), 2.58 (m, 1H), 3.60 (d, $J=4.8$ Hz, 1H), 3.9 (d, $J=6.6$ Hz, 1H), 4.16 (d, $J=8.4$ Hz, 1H), 4.31 (d, $J=8.4$ Hz, 1H), 4.79 (d, $J=1, 2.6$ Hz, 1H), 4.92 (d, $J=8.0$ Hz, 1H), 5.53 (dd, $J=7.3, 10.2$ Hz, 1H), 5.65 (d, $J=6.6$ Hz, 1H), 5.80 (dd, $J=2.2, 9.2$ Hz, 1H), 6.15 (dd, $J=8.8, 8.8$ Hz, 1H), 6.22 (s, 1H), 7.10 (d, $J=9.2$ Hz, 1H), 7.35 (m, 1H), 7.41 (m, 4H), 7.48 (m, 5H), 7.60 (t, $J=7$ Hz, 1H), 7.74 (d, $J=7.3$ Hz, 2H), 8.09 (7.32 Hz, 2H); ^{13}C NMR (125 MHz, CD_3OD) δ 10.07, 12.91, 13.39, 19.31, 20.73, 21.85, 22.03, 23.78, 25.43, 30.98, 32.94, 33.65, 35.21, 43.30, 47.24, 55.93, 56.36, 56.45, 70.85, 71.47, 73.50, 74.55, 75.24, 75.98, 77.55, 80.64, 83.84, 127.16, 127.17, 127.67, 128.26, 128.39, 128.41, 129.86, 129.98, 131.52, 133.13, 133.29, 134.31, 138.67, 140.71, 166.26, 169.07, 169.28, 170.64, 173.13, 202.30. LRMS (electrospray) M/Z observed for $\text{C}_{53}\text{H}_{61}\text{NO}_{15}$ ($M + H$): 952.8, and M/Z observed for $\text{C}_{53}\text{H}_{61}\text{NO}_{15}\text{Na}$ ($m + \text{Na}$): 974.8.

Claims

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method for the preparation of a taxane derivative of formula




wherein R is a branched or unbranched alkyl, alkenyl, alkynyl group or aryl group, comprising the steps of:

reacting a solution of paclitaxel with a reagent that causes the esterification of the alcohols located at the 2' and 7 positions of paclitaxel; and replacing the ester located at the 2' with an alcohol.

2. The method of claim 1, wherein said reagent is a carboxylic acid.
3. The method of claim 1, wherein said reagent is an acid halide.
4. The method of claim 1, wherein said reagent is an acid anhydride.
5. The method of claim 4, wherein said acid anhydride is hexanoic anhydride.
6. The method of claim 3, wherein said acid halide is hexanoic halide.
7. The method of claim 2, wherein said carboxylic acid is hexanoic acid.
8. The method of claim 1, wherein said replacing step takes places in an acid solution.
9. The method of claim 1, wherein said replacing step takes places in a basic solution.
10. A method for the preparation of a taxane derivative of formula

17




comprising the steps of:

reacting hexanoic anhydride with a solution of paclitaxel thereby producing *bis*-2',7-hexanoyltaxol;


hydrolyzing the 2' hexanoyl group.

11. The method of claim 8, wherein said hydrolyzing step takes place in alkaline conditions.

12. A taxane derivative of formula:




13. A taxane derivative of formula:



wherein R is a branched or unbranched alkyl, alkenyl, alkynyl group or aryl group.


14. The taxane derivative of claim 12, wherein R is said unbranched alkyl group.
15. The taxane derivative of claim 13, wherein said unbranched alkyl group is hexanyl.
16. A method for treating cancer, which comprises administering to a patient suffering from said cancer a taxane derivative of formula:

5




wherein R is a branched or unbranched alkyl, alkenyl, alkynyl group or aryl group.

17. The method according to claim 15, wherein said cancer is selected from the group of cancers consisting of leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, and breast cancer.
18. A method for treating multidrug resistant cancers, which comprises administering to a patient suffering from said multidrug resistant cancers a taxane derivative of formula:




15 wherein R is a branched or unbranched alkyl, alkenyl, alkynyl group or aryl group.

1/11



CARBOXYLIC ACID, HEAT
OR
ACID HALIDE
OR
ACID ANHYDRIDE



ACID HYDROLISIS
OR
ALKALINE HYDROLISIS
OR
REDUCTION




FIG. 1
SUBSTITUTE SHEET (RULE 26)

2/11






FIG. 1A



SUBSTITUTE SHEET (RULE 26)

3/11



SUBSTITUTE SHEET (RULE 26)

4/11



5/11




FIG. 4a






FIG. 4b



SUBSTITUTE SHEET (RULE 26)

6/11





SUBSTITUTE SHEET (RULE 26)

7/11





SUBSTITUTE SHEET (RULE 26)

8/11



9/11



SUBSTITUTE SHEET (RULE 26)

10/11




FIG. 9a




PC-3 —○—
DU-145 --◇--

FIG. 9b

PC-3 —○—
DU-145 --◇--

SUBSTITUTE SHEET (RULE 26)

11/11



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/07880

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07D 305/14 ; A61K 31/335

US CL : 549/510, 511; 514/449

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 549/510, 511; 514/449

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
none

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,721,268 A (HOLTON et al) 24 February 1998, columns 2, 25 and 26.	1-18

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 MAY 1999

Date of mailing of the international search report

02 JUN 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BA K. TRINH

Telephone No. (703) 308-1235